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Cancer cells are highly dependent on glycolysis to supply the energy and intermediates required for cell
growth and proliferation. The enzyme 6-phosphofructo-1-kinase (PFK) is critical for glycolysis, and its
activity is directly correlated with cellular glucose consumption. Resveratrol is a potential anti-tumoral
drug that decreases glucose metabolism and viability in cancer cells. However, the mechanism
involved in resveratrol-mediated anti-tumor activity is not entirely clear. In this work, it is demonstrated
that resveratrol decreases viability, glucose consumption and ATP content in the human breast cancer
cell line MCF-7. These effects are directly correlated with PFK inhibition by resveratrol in these cells.
Moreover, resveratrol directly inhibits puriﬁed PFK, promoting the dissociation of the enzyme from fully
active tetramers into less active dimers. This effect is exacerbated by known negative regulators of the
enzyme, such as ATP and citrate. On the other hand, positive modulators that stabilize the tetrameric
form of the enzyme, such as fructose-2,6-bisphosphate and ADP, prevent the inhibition of PFK activity by
resveratrol, an effect not observed with increased pH. In summary, our results provide evidence that
resveratrol directly inhibits PFK activity, therefore disrupting glucose metabolism and reducing viability
in cancer cells.
 2013 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Energy metabolism is often altered in neoplastic cells [1]. Many
studies have shown that cancer cells are highly dependent on
glycolytic metabolism [2e4] because this bioenergetic pathway is
able to generate metabolic products to support the energy de-
mands of tumor growth and proliferation [5]. Thus, inhibitors of
glycolytic metabolism that could reduce the tumoral energy supply
are emerging as potential drugs to combat this disease [4,6,7].
The enzyme 6-phosphofructo-1-kinase (EC 2.7.1.11, or PFK) is
critical for glycolytic metabolism, catalyzing the transfer of a
phosphate from ATP to fructose-6-phosphate (F6P) to produce
fructose-1,6-bisphosphate and adenosine diphosphate (ADP).
Expression levels of the three different PFK isoforms are tissue-ADP, adenosine diphosphate;
hosphate; PFK, 6-phospho-
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nder the Elsevier OA license.speciﬁc: skeletal muscle is unique in that it expresses only PFK-
M, whereas all other tissues express distinct levels of the three
isoforms [8,9]. This enzyme is characterized by complex regulatory
mechanisms, among them allosteric regulation, oligomerization,
subcellular localization, interaction with other proteins and cova-
lent modiﬁcations [9,10]. The metabolic alterations found in cancer
cells have been correlated with changes in the expression pattern
and activity of PFK [1], and PFK inhibition can lead to cell death in
human breast carcinoma cell lines [4,7] and human breast cancer
tissues [11]. Thus, PFK appears to be a promising target for the
development of new drugs with anti-tumoral activity.
Resveratrol, a polyphenolic compound found mainly in grapes,
can decrease the rate of tumor cell growth [12,13]. This effect may be
related to the capacity of resveratrol to reduce glucose uptake and
lactate production [14]. However, the mechanism of action of this
promising compound is not well understood. Because neoplastic
cells depend preferentially on anaerobic metabolism instead of
aerobic metabolism, and because PFK is a pacemaker enzyme
capable of regulating the glycolytic pathway, we aimed to investigate
whether resveratrol modulates survival, glucose metabolism and
Fig. 1. SDS-PAGE of the puriﬁed PFK from rabbit skeletal muscle. SDS-PAGE (8%
acrylamide) was performed as described in materials and methods. Lane 1: Final pu-
riﬁed PFK. Lanes 2e6: Previous salting-out steps. Lane 1: Molecular weight markers
used - a2-macroglobulin from equine serum (180 kDa), b-galactosidase from E. coli
(116 kDa), Lactoferrin from human milk (90 kDa), pyruvate kinase from rabbit muscle
(58 kDa), fumarase from porcine heart (48.5 kDa), lactic dehydrogenase from rabbit
muscle (36.5 kDa) and triosephosphate isomerase from rabbit muscle (26.6 kDa). This
is a representative gel of a series of puriﬁcations presenting the same pattern.
L.S. Gomez et al. / Biochimie 95 (2013) 1336e1343 1337PFK activity in the breast cancer cell line MCF-7. Our results provide
further insight into the mechanism of PFK inhibition by resveratrol.
2. Materials and methods
2.1. MCF-7 breast cancer cell culture and assays
The breast cancer cell line MCF-7 was cultured in DMEM sup-
plemented with 4.5 mM glucose, 10% (v/v) fetal bovine serum and
2 mM glutamine (except when indicated that cells were grown in
the absence of glutamine) at 37 C until conﬂuence was achieved.
Then, the medium was removed, and cells were seeded in 96-well
plates with fresh medium in the absence or presence of different
concentrations of resveratrol (1, 5, 15, 50 or 100 mM; Sigma
Chemical, St. Louis, MO, USA; 99% purity) and incubated for 24 h.
Controls were also performed in the absence or presence of 2.5%
DMSO to ensure the lack of cytotoxicity of DMSO. After this incu-
bation, the medium was removed and used to evaluate the meta-
bolic effects of resveratrol treatment. Cell viability was assessed by
the MTT assay [7]. Glucose consumption was measured using a
coupled enzyme system (Glucox 500, Doles Ltda, Brazil) [1]. LDH
leakage was determined by measuring the total LDH activity in the
culture media based on conversion of NADH to NADþ [1]. Lactate
production was determined by assessing the lactate content in the
culture media through monitoring the formation of NADH in the
presence of exogenous LDH and NADþ [15]. The intracellular ATP
content was measured using a system based on a luciferin-
luciferase assay (PerkinElmer ATPLite) with a VICTOR3 multilabel
reader (PerkinElmer) [4]. PFK activity was measured spectropho-
tometrically using a coupled enzyme system that relies on the
oxidation of NADH. The basic medium contained 50 mM Tris-HCl
(pH 7.4), 5 mM MgCl2, 1 mM F6P, 1 mM ATP, 0.2 mM NADH, 2 U/
ml aldolase, 4 U/ml triosephosphate isomerase and 2 U/ml a-
glycerophosphate dehydrogenase [4]. Determination of F1,6BP/F6P
ratio was performed as described previously [16]. Measurements
from cell-based assayswere corrected by the number of viable cells.
2.2. Radioassay for PFK activity
Puriﬁed PFK activity was assessed through the radiometric
method developed by Sola-Penna et al. [17], with the modiﬁcations
introduced by Zancan and Sola-Penna [18]. Brieﬂy, PFK was assayed
in a basicmedium containing 50mMTris-HCl (pH 7.4), 5mMMgCl2,
5 mM (NH4)2SO4, 1 mM F6P, 1 mM [g-32P]ATP and 1 mg/ml puriﬁed
PFK. The pH and the concentrations of substrates, enzyme, and
resveratrol may vary depending on the experiment, as indicated in
the legends or ﬁgures. All reactions were performed at 37 C with
the exception of those shown in Fig. 6 (50 C). All experiments were
performed in the absence or presence of 2.5% DMSO. Controls
throughout thework were performed only in the presence of DMSO
because the enzyme activity is not affected by this concentration of
DMSO. PFK activity was reported in m-units, where 1 m-unit is
equal to the formation of 1 nmol of F1,6BP per minute of reaction.
PFK was puriﬁed from rabbit skeletal muscle, and the purity of the
enzyme was 99.9%, such as evaluated by SDS-PAGE (Fig. 1) per-
formed according to [19]. Puriﬁed PFK for all experiments was ob-
tained according to the method developed by Kemp [20] with the
modiﬁcations introduced by Hesterberg et al. [21].
2.3. Intrinsic ﬂuorescence measurements
PFK intrinsic ﬂuorescence measurements were performed as
described previously byMarinho-Carvalho [22] and Leite et al. [16].
Measurements were taken in the presence of different enzyme
concentrations (0.2, 1 and 5 mg/ml) and in the absence or presenceof 15 mM resveratrol. The excitation wavelength was ﬁxed at
280 nm, and the ﬂuorescence emission was scanned from 300 to
400 nm. The centers of mass of the intrinsic ﬂuorescence spectra
(c.m.) were calculated using equation (1):
c:m: ¼
P
l$IlP
Il
(1)
where l is the wavelength, and Il is the ﬂuorescence intensity at a
given l.
2.4. Statistical analysis and calculations
The results are expressed asmeans standard error. Analyzes of
the data and linear and non-linear regression were performed us-
ing Sigma Plot software (v. 10.0, Systat Inc., CA, USA) integrated
with the software SigmaStat (v. 3.2, Systat Inc. CA, USA). Values for
each group were compared by Student’s t-test, and the differences
were considered signiﬁcant if P < 0.05.
Kinetic parameters for ATP effects on PFK were calculated
through non-linear regression using the experimental data to ﬁt
the parameters of the equation:
v ¼
Vmax½ATPn1
Kn10:5 þ ½ATPn1
$½ATPn2
In20:5 þ ½ATPn2
(2)
where v is the PFK activity calculated for a given concentration of
ATP ([ATP]), Vmax is the maximal velocity calculated, K0.5 is the af-
ﬁnity constant for the catalytic component of the ATP curve, which
is equal to the concentration of F6P responsible for half activation of
the enzyme by ATP, n1 is the cooperativity index for this catalytic
component, I0.5 is the afﬁnity constant for the inhibitory compo-
nent of the ATP curve, which is equal to the concentration of ATP
responsible for 50% of themaximal inhibition of the enzyme by ATP,
and n2 is the cooperativity index for this inhibitory component.
Kinetic parameters for F6P effects on PFK were calculated
through non-linear regression using the experimental data to ﬁt
the parameters of the equation:
v ¼ Vmax½F6P
n
Kn0:5 þ ½ATPn
(3)
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F6P ([F6P]), Vmax is the maximal velocity calculated at saturating
concentrations of F6P, K0.5 is the afﬁnity constant for F6P, which is
equal to the concentration of F6P responsible for half-activation of
the enzyme by F6P, and n is the cooperativity index for this
phenomenon.
3. Results
Many studies have shown that resveratrol is able to control the
growth of neoplastic cells [12,14]. First, we investigated whether
resveratrol modulates survival, glucose metabolism and PFK ac-
tivity in MCF-7 breast cancer cells after 24 h of preincubation with
this compound. Fig. 2A shows that resveratrol decreases the
reduction of MTT in a concentration-dependent manner. The
higher concentration of resveratrol (100 mM) decreases cell viability
by approximately 40%. In addition, resveratrol increases lactate
dehydrogenase (LDH) leakage in the cell culture media (Fig. 2A),
indicating the loss of cell integrity and viability. Thus, these results
conﬁrm data from previous literature showing that resveratrol
decreases cell viability in the MCF-7 cell line [23]. Seeking to
elucidate the mechanisms of these effects, the glucose consump-
tion and lactate production were analyzed in MCF-7 cells culturedFig. 2. Effects of different concentrations of resveratrol on MCF-7 cells viability, glucose con
DMEM until conﬂuence. After that, the medium was removed and fresh medium containing
under these conditions. Controls were done in the presence of DMSO. Treated cells were us
bars); panel B, glucose consumption (black bars) and lactate production (gray bars); panel
absolute glucose consumption rate in the absence of resveratrol was 31.3  0.8 nmol/h
10.6  0.3 nmol/h  107 cells. The absolute value for ATP content in the absence of resveratr
cells and of F6P was 0.7  0.1 nmol/107 cells. The experimental procedures are described in
experiments (n ¼ 4e8). *P < 0.05 compared with respective control in the absence of resvin the presence of different concentrations of resveratrol for 24 h
Fig. 2B shows that resveratrol decreases glucose consumption in a
concentration-dependent manner, resulting in signiﬁcant effects
even at lower resveratrol concentrations such as 1 mM. Interest-
ingly, resveratrol increases lactate production at concentrations
higher than 15 mM, which is probably related to increased gluta-
mine oxidation. This hypothesis is conﬁrmed evaluating glucose
consumption and lactate production in a glutamine-free culture
medium (Fig. 2B). Under this condition, resveratrol also decreases
lactate production by MCF-7 cells. It is important to notice that
glucose consumption is affected in a similar manner in the presence
or the absence of glutamine in the culture medium (Fig. 2B), as well
as cell viability (data not shown). Similar to the effects of resveratrol
upon the MTT reduction and glucose consumption, this compound
also decreases cellular ATP content (Fig. 2C) by approximately 16%
at 1 mM resveratrol and 50% at 100 mM resveratrol. To understand
themechanism bywhich resveratrol affects energymetabolism, we
analyzed the activity of PFK, the major glycolytic regulatory
enzyme, in the presence of different concentrations of resveratrol.
Fig. 2D shows that PFK activity is inhibited by resveratrol in a
concentration-dependent manner. Moreover, 100 mM resveratrol
decreases the F1,6BP/F6P ratio in w25%, corroborating that
resveratrol intracellularly inhibits PFK. Altogether, the degree ofsumption, lactate production, ATP content and PFK activity. MCF-7 cells were grown in
the desired concentrations of resveratrol was added and cells were incubated for 24 h
ed to evaluate: Panel A, viability by MTT reduction (black bars) and LDH leakage (gray
C, intracellular ATP content; panel D, PFK activity; panel D inset, F1,6BP/F6P ratio. The
 107 cells. The absolute lactate production rate in the absence of resveratrol was
ol was 17.3  1.1 nmol/107 cells. The absolute amount of F1,6BP was 2.1  1.5 nmol/107
material and methods. Data represent the mean  standard error of 4e8 independent
eratrol (Student’s t-test). The origin of the ordinates is suppressed in panels B and D.
L.S. Gomez et al. / Biochimie 95 (2013) 1336e1343 1339PFK inhibition by resveratrol is highly correlated with decreased
cell viability, glucose consumption and intracellular ATP content,
suggesting PFK as a target of resveratrol in MCF-7 cells.
Our group has previously shown that other drugs that cause
these effects, such as clotrimazole [24] and acetylsalicylic acid [7],
can directly inhibit PFK, glucose consumption and cell viability in
MCF-7 cells. Thus, to investigate whether resveratrol could be
acting directly on PFK, the activity of the puriﬁed enzyme was
analyzed in the presence of different concentrations of this com-
pound. Fig. 3 shows that resveratrol inhibits the activity of PFK in a
concentration-dependent manner, with approximately 50% inhi-
bition of total enzyme activity achieved in the presence of 15 mM of
the polyphenol. This concentration was used for subsequent ex-
periments because it resulted in the greater degree of inhibition.
These experiments were performed without pre-incubation of the
enzyme with resveratrol, demonstrating the rapid effect of this
inhibitor.
To investigate whether the inhibitory effect of resveratrol could
be due to alterations in the kinetic parameters of PFK, wemeasured
the enzyme activity in the presence of different concentrations of
its substrates, ATP and F6P. Resveratrol inhibits PFK activity at all
concentrations of F6P tested (Fig. 4A). PFK is also inhibited by
resveratrol at all concentrations of ATP (Fig. 4B). Moreover, for the
F6P substrate, resveratrol increases the Km (from 0.14  0.01 to
0.22  0.02 mM; P < 0.05), thus decreasing the afﬁnity, and also
decreases the Vmax (from 65 3 to 33 3mU/mg; P< 0.05) without
altering the cooperativity index (from 1.5  0.4 to 1.1  0.3)
(Fig. 4A). In relation to ATP, resveratrol also decreases the afﬁnity of
the PFK catalytic site for this substrate, as supported by the increase
in K0.5 (from 0.34  0.01 to 0.40  0.01; P < 0.05); without modi-
fying the cooperativity index for the stimulatory component of the
enzyme (1.3  0.1 and 1.5  0.1 for control and resveratrol,
respectively). However, despite the signiﬁcantly reduced apparent
maximal velocity of PFK (from 65  3 to 36  2 mU/mg; P < 0.05),
resveratrol does not alter either the afﬁnity for the inhibitory
component, I0.5, (1.9  0.1 and 2.2  0.1 mM for control and
resveratrol, respectively) or the cooperativity index (3.0  0.4 and
4.0  0.3 for control and resveratrol, respectively) of PFK for ATP
(Fig. 4B).Fig. 3. Effects of different concentrations of resveratrol on puriﬁed PFK activity. The
PFK activity (1 mg/ml) was assayed in the absence (ﬁlled circle, control) or presence of
1, 5, 10, 15, 25 or 50 mM of resveratrol (ﬁlled circles) at pH 7.4. The PFK activity was
measured as described in material and methods. *P < 0.05 compared to control
(Student’s t-test). Values are means  standard error of six independent experiments
(n ¼ 6).The PFK concentration inﬂuences the oligomerization state of
the enzyme. Lower concentrations of PFK favor the formation of
dimers, which are quite inactive, while higher concentrations
stabilize the tetrameric form, which is fully active [9,16,25]. In
previous work, it was shown that the strong inhibitory effects of
lactate and acetylsalicylic acid on PFK are attenuated when the
enzyme concentration is increased [3,7]. Therefore, the inhibitory
effect of these substances may be due to dissociation of the PFK
from the tetrameric (higher speciﬁc activity) to the dimeric (lower
speciﬁc activity) form. After observing that resveratrol directly
inhibits PFK activity, we sought to investigate the mechanism by
which this effect was occurring. First, we analyzed the effect of
15 mM resveratrol on the activity of PFK in the presence of
increasing concentrations of the enzyme (0.2, 1, 5, 10 and 15 mg/
ml). Fig. 5 shows that resveratrol markedly inhibits PFK activity at
low enzyme concentrations (0.2 mg/ml). However, increasing the
enzyme concentration decreases the inhibition caused by resver-
atrol, and this inhibitory effect is completely abolished at 10 mg/ml
enzyme. This effect correlates with the tetramerization and
increased enzyme stability at high enzyme concentrations, as
previously shown in other studies [3,7,26]. In addition, we eval-
uated the effects of resveratrol on the intrinsic ﬂuorescence
spectrum of the PFK in order to verify whether resveratrol mod-
ulates the PFK oligomeric structure. The results show that
resveratrol increases the center of mass of the PFK intrinsic ﬂuo-
rescence spectrum, especially at lower enzyme concentrations
(0.2 mg/ml) (Fig. 6). However, increasing the concentration of PFK
to 5 mg/ml prevents this resveratrol-induced effect. The results
shown in Fig. 6 are highly correlated with the data shown in Fig. 5,
suggesting that a high enzyme concentration increases the for-
mation and stabilization of more complex oligomeric forms of the
enzyme (Fig. 6), thus preventing the inhibitory effects of resver-
atrol (Fig. 5).
Because high temperature can be used to dissociate the enzyme,
and hence destabilize it and reduce its activity [24], we evaluated
the effect of resveratrol (15 mM) on the activity of PFK (1 mg/ml) pre-
incubated at 50 C for different periods of time (Fig. 7). Resveratrol
is able to inhibit PFK activity by approximately 50% at 37 C (time 0).
In either the absence or presence of resveratrol, PFK activity is lost
over time during incubation at 50 C due to the denaturation of the
enzyme. However, in the presence of resveratrol, there is marked
inhibition of PFK activity, as can be better observed when the ab-
solute values of activity (Fig. 7A) are expressed as relatives values,
with the activity of the enzyme at room temperature set as 100%
(Fig. 7B). These results, together with Figs. 5 and 6, suggest that
resveratrol may interact directly with PFK, resulting in a synergistic
effect with temperature-mediated enzyme destabilization.
Furthermore, these results indicate that the formation of inactive
dimers may be the mechanism by which resveratrol mediates PFK
inhibition.
PFK loses most of its regulatory properties at pH 8.2, when the
tetrameric conformation of the enzyme is favored and the enzyme
functions at its maximal velocity. In contrast, a lower pH renders
the enzyme more susceptible to inhibition by allosteric regulators
[3,9,10,27]. Thus, the effect of resveratrol on the downregulation of
PFK activity was analyzed at different pH values. Surprisingly, and
in contrast to previous studies demonstrating that PFK is not sus-
ceptible to inhibitors at higher pH [3,9], our results show that
resveratrol inhibits PFK activity at all pH values above 6 (Fig. 8). In
addition, even at pH values at which the enzyme reaches its
maximum velocity (pH 8.0 and 8.5), resveratrol maintains its
inhibitory effect on enzyme activity (Fig. 9). This result suggests
that resveratrol could be modulating PFK activity and, conse-
quently, the energy supply to cancer cells even over a large range of
intracellular pH values.
Fig. 4. Effects of resveratrol on puriﬁed PFK activity assessed at different concentrations of F6P or ATP. The PFK activity (1 mg/ml) was assayed in the absence (ﬁlled circles, control)
or presence of 15 mM of resveratrol (white circles) in the presence of different concentrations of the substrates of enzyme at pH 7.4. Panel A: PFK activity in the presence of varying
concentrations of F6P (0.025, 0.05, 0.075, 0.1, 0.3, 0.5, 0.8, 1.0 and 2.0 mM). Panel B: PFK activity in the presence of varying concentrations of ATP (0.1, 0.3, 0.5, 0.8, 1.0, 3.0 and
5.0 mM). The PFK activity was measured as described in material and methods. *P < 0.05 compared to control (Student’s t-test). Values are means  standard error of ﬁve to seven
independent experiments (n ¼ 5e7).
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to other well-characterized negative and positive regulators of PFK.
This enzyme is positively modulated by ATP (at concentrations
below 1 mM), fructose-2,6-bisphosphate (F2,6BP), phosphoryla-
tion, adenosine monophosphate (AMP), ADP and F-actin. In addi-
tion, ATP (at concentrations greater than 1 mM), citrate and lactate
function as negative modulators of the enzyme [9,10,16]. Therefore,
we evaluated the effects of resveratrol on PFK activity in the pres-
ence of different positive and negative modulators of the enzyme.
Resveratrol inhibits PFK activity by approximately 50% (Fig. 9), in
accordance with the effect observed previously for 15 mMFig. 5. Effects of resveratrol on puriﬁed PFK activity assessed at different concentra-
tions of the enzyme. The PFK activity was assayed in the presence of different enzyme
concentrations (0.2, 1, 5, 10 or 15 mg/ml) in the absence (black bars, control) or presence
of 15 mM of resveratrol (gray bars) at pH 7.4. The PFK activity was measured as
described in material and methods. Values are means  standard error of seven to nine
independent experiments (n ¼ 7e9) and PFK activity for each enzyme concentration
was considered as 100%. *P < 0.05 compared to respective control (Student’s t-test).resveratrol (Fig. 2). However, the inhibitory effect of resveratrol is
attenuated by the presence of 100 nM F2,6BP. Furthermore, F-actin
(50 mg/ml) and ADP (10 mM) are able to partially reverse the
resveratrol-mediated inhibition of PFK. ATP (5 mM), citrate
(10 mM) and lactate (10 mM) inhibit PFK activity (Fig. 9). In addi-
tion to these effects, resveratrol is able to increase the degree of
inhibition by citrate and ATP (Fig. 9). Together, these results show
that resveratrol can modulate the activity of PFK independently of
some positive allosteric factors, such as F-actin and ADP and that
the presence of some negative regulatory factors may have addi-
tional effects on resveratrol-mediated PFK inhibition.Fig. 6. Effects of resveratrol on the center of mass of PFK intrinsic ﬂuorescence spectra
measured at different enzyme concentrations. The center of mass was determined in
the presence of different enzyme concentrations (0.2, 1 or 5 mg/ml) in the absence
(black bars, control) or presence (gray bars) of 15 mM of resveratrol at pH 7.4. The
center of mass was measured as described in material and methods. Values are
means  standard error of four independent experiments (n ¼ 4). *P < 0.05 compared
to respective control (Student’s t-test).
Fig. 7. Effects of resveratrol upon the time course of thermal inactivation of puriﬁed PFK. PFK (1 mg/ml) was pre-incubated at 50 C in the absence (ﬁlled circles, control) or presence
of 15 mM of resveratrol (empty circles) at pH 7.4. At the times indicated on abscissa, aliquots were withdrawn and the PFK activity was measured as described in material and
methods. Panel A and panel B represents the absolute and relative PFK activity, respectively. PFK activity without pre-incubation (time 0) was considered as 100% in panel B. Values
are means  standard error of six independent experiments (n ¼ 6). *P < 0.05 compared to resveratrol at the same time of pre-incubation (Student’s t-test).
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Cancer cells are highly dependent on glucose metabolism to
maintain high levels of glycolytic intermediates and to meet the
additional requirements for growth, division andproliferation [2,4,5].
This dependence of cancer cells on glucose metabolism, even in the
presence of oxygen, is known as the Warburg Effect. Recent studies
have provided evidence that inhibition of PFK, the key glycolytic
enzyme, may control cell viability in cancer cells [7,24,28,29].
Although the mechanisms mediating these effects are still not clear,
PFK inactivation is directly correlated to apoptosis induction, reduced
glycolysis and a reduction in the cellular ATP supply [30].
Resveratrol is a phytoalexin that has been demonstrated to
possess a wide variety of biological activities, including longevity,
antidiabetic and anticancer properties [12,31]. Recently, it wasFig. 8. Effects of resveratrol on puriﬁed PFK activity assessed at different pHs. The PFK
activity (1 mg/ml) was assayed in the absence (black bars, control) or presence (gray
bars) of 15 mM of resveratrol at different pHs (6.0, 6.5, 7.0, 7.4, 8.0 or 8.5). The PFK
activity was measured as described in material and methods. Values are
means  standard error of six independent experiments (n ¼ 6). *P < 0.05 compared to
respective control (Student’s t-test).demonstrated that resveratrol increases cyclic AMP levels by
competitively inhibiting phosphodiesterases (PDE), thus leading to
the activation of AMP-activated protein kinase (AMPK) and
ameliorating aging-related metabolic phenotypes [32]. In addition,
resveratrol has received wide attention for its ability to induce
apoptotic cell death in many different cancer cell lines [33e35].
However, its mechanism of action is still unclear.
Here, we have shown that resveratrol decreases MCF-7 breast
cancer cell viability, glucose consumption, intracellular ATP content
and PFK activity (Fig. 2). Curiously, resveratrol promotes increased
lactate production due to the augmented oxidation of glutamine
(Fig. 2). This whole picture, i.e. diminished glucose consumption
and augmented lactate production due to an increased glutamineFig. 9. Effects of resveratrol on puriﬁed PFK activity assessed in the presence of
different negatives and positives enzyme regulators. The effects of positive modulators
(100 nM F2,6BP, 50 mg/ml F-actin or 10 mM ADP) and negative modulators (10 mM
citrate, 5 mM ATP or 10 mM lactate) upon PFK activity (1 mg/ml) was assayed in the
absence (black bars, control) or presence (gray bars) of 15 mM of resveratrol at pH 7.4.
The PFK activity was measured as described in materials and methods. Values are
means  standard error of seven independent experiments (n ¼ 7). *P < 0.05
compared to respective control in the absence of resveratrol (Student’s t-test).
#P < 0.05 compared to control in the absence of resveratrol (Student’s t-test).
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hedgehog signaling pathway [36], which has been described to be
activated by resveratrol [37]. These metabolic alterations are
directly correlated with the induction of apoptosis [30,37].
Furthermore, with the exception of increased lactate production,
these effects were observed in the presence of low resveratrol
concentrations (2.5e10 mM) similar to those used in other studies
[38,39].
Previous work from our group has shown that clotrimazole, an
antifungal agent, and acetylsalicylic acid, an anti-inﬂammatory
drug, modulate cancer cell viability by directly targeting PFK
[4,7,24,28]. In addition, clotrimazole disrupts glycolysis in human
breast cancer without affecting non-tumoral tissues [11]. In the
present study, we found that resveratrol also speciﬁcally inhibits
puriﬁed PFK in a concentration-dependent manner (Fig. 3). The
speciﬁcity for resveratrol inhibition of PFK is even stronger, as
evidenced by the observation that the inhibitory concentrations are
similar in the cell culture (Fig. 2D) and for the puriﬁed PFK (Fig. 3).
However, the intracellular concentrations of resveratrol were not
determined.
Cancer cells express all isoforms of PFK [1], while skeletal
muscle cells express only PFK-M [21], and once translated, PFK
monomers can rapidly associate into homo- or heteroligomers
[21,27]. Thus, the results suggest that PFK-M is a possible target of
resveratrol. However, it is difﬁcult to know if resveratrol could
speciﬁcally modulate the other isoforms (L and P) given the rapid
formation of heteroligomers composed of M, L and P isoforms.
PFK can be regulated by the oligomeric transition between tet-
ramers and dimers, which are much less active than tetramers. This
enzyme can also be negatively regulated by physiological effectors
such as ATP (>1 mM), citrate and lactate. Some drugs also nega-
tivelymodulate the enzyme by promoting dissociation of tetramers
into dimers [7,24,28]. However, these inhibitors are counteracted
by positive regulators such as F2,6BP and ADP [3,22,26,29,40]. Our
results suggest that resveratrol also downregulates PFK through
dissociation of the enzyme tetramers into dimers, as detected by
the increased center of mass of the PFK intrinsic ﬂuorescence
spectrum (Fig. 6). In agreement with these results, resveratrol has
an additional effect on PFK inhibition by ATP (>1 mM) (Fig. 9),
citrate (Fig. 9) and high temperature (50 C) (Fig. 7), all of which
accelerate the loss of enzyme activity by promoting dimerization.
However, increasing the concentration of the enzyme, which favors
the formation of tetramers, prevents the PFK inhibition caused by
resveratrol. In addition, it is interesting that resveratrol inhibits PFK
even at higher pH values (Fig. 8) because we expected that these
conditions (pH 8.0 and 8.5) would stabilize more complex oligo-
meric forms of the enzyme and thereby prevent inhibition. Thus,
resveratrol may prevent oligomerization of the enzyme and reduce
its maximal activity. This effect suggests that resveratrol could act
over the wide range of intracellular pH values observed in tumors
[41].
Altogether, our results indicate that resveratrol decreases cell
viability in the human breast cancer cell line MCF-7 by reducing
glucose consumption and ATP content, an effect that could be
related to PFK inhibition. This relationship is supported by results
demonstrating that resveratrol directly inhibits the activity of pu-
riﬁed PFK, thus suggesting a new target in the mechanism through
which resveratrol induces its antitumorigenic effects.
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